Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Anti PD-L1 Durvalumab Combined With Cetuximab and Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: a Phase I/II Study

NCT03051906 is registered in ClinicalTrials.gov with Azienda Ospedaliero-Universitaria Careggi as lead sponsor.

NCT NCT03051906
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03051906 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Anti PD-L1 Durvalumab Combined With Cetuximab and Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: a Phase I/II Study
Lead sponsor
Azienda Ospedaliero-Universitaria Careggi
Phase
Phase 1/2
Overall status
Unknown status
Start date
January 31, 2018
Completion date
January 31, 2025
Enrollment
69 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck neoplasms